TCF7L2 and melanoma: In conclusion, we propose a PRRX1/TCF7L2-Sp1/miR-29 regulatory axis, which involves Wnt/β-catenin and MAPK signaling pathways, as a key mechanism controlling SPARC expression in melanoma.